Jing-Yuan Xu
12PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (12)
Sort by Publication Date:
|Mar 20, 2026
Antitumor Cytisine-Platinum(IV) Prodrugs Potentiate Crosstalk between Endoplasmic Reticulum and Mitochondria through Calcium Overload Accompanied by Immunogenic Cell Death.Ruo-Xi Sang, Yang-Qi Wang, Xiu-Yuan Wu
|Jul 09, 2025
Precision-Oriented Theophylline-Platinum(IV) Prodrugs: Eliciting Synthetic Lethality in BRCA1-Deficient Ovarian Cancer with Enhanced Efficacy and Reduced Toxicity In Vitro and In Vivo.Xiao-Meng Liu, Zhen-Zhen Zhu, Qing-Tian Li
|Apr 23, 2025
Fluoxetine-Conjugated Platinum(IV) Prodrugs Targeting eEF2K and Conquering Multidrug Resistance against Triple-Negative Breast Cancer.Jia-Qian Wang, Xiao-Meng Liu, Zi-Shuo Zhu
|Apr 23, 2025
Correction to "Novel Indoleamine-2,3-dioxygenase-Targeted Pt(IV) Prodrugs Regulate the Tumor Immune Microenvironment to Achieve Chemoimmunotherapy In Vitro and In Vivo".Zhe Li, Xiao-Meng Liu, Fei Tan
|Feb 07, 2025
Novel Indoleamine-2,3-Dioxygenase-Targeted Pt(IV) Prodrugs Regulate the Tumor Immune Microenvironment to Achieve Chemoimmunotherapy In Vitro and In Vivo.Zhe Li, Xiao-Meng Liu, Fei Tan
|Aug 26, 2024
Pt(iv) derivatives of cisplatin and oxaliplatin bearing an EMT-related TMEM16A/COX-2-selective dual inhibitor against colorectal cancer cells HCT116.Zhong-Ying Ma, Xiao-Jing Ding, Zhen-Zhen Zhu
Pageof 2
